MétaCan
Menu
Back to cohort

Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.

2016· article· en· W2891692504 on OpenAlexaff
María‐Victoria Mateos, Tamás Masszi, Norbert Grząśko, Markus Hansson, Irwindeep Sandhu, Luděk Pour, Luísa Viterbo, Sharon Jackson, Anne‐Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Helgi van de Velde, Paul G. Richardson, Philippe Moreau

Bibliographic record

VenueJournal of Clinical Oncology · 2016
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsUniversity of Alberta
Fundersnot available
KeywordsLenalidomideMedicineIxazomibMultiple myelomaPlaceboInternal medicineDexamethasoneOncologyRefractory (planetary science)CarfilzomibPathology

Abstract

fetched live from OpenAlex

8039 Background: TOURMALINE-MM1 (NCT01564537) demonstrated improved PFS with IRd vs placebo-Rd (median 20.6 vs 14.7 mos; HR 0.74) in pts with RRMM after at least 1 prior therapy (Moreau et al, ASH 2015). Efficacy and safety of IRd vs placebo-Rd were analyzed according to prior proteasome inhibitor (PI) and prior thalidomide (thal)/lenalidomide (R) exposure. Methods: Pts were randomized 1:1 to receive IRd or placebo-Rd until disease progression or unacceptable toxicity. Pts with prior PI- and thal/R-based regimens, and pts refractory to thal, were eligible, but not pts refractory to PI- or R-based prior therapy. Results: Of 722 pts, 69% had prior PI therapy (< 1% prior carfilzomib) and 55% had prior thal/R therapy, including 45% prior thal (12% thal-refractory) and 12% prior R. Prior therapies were balanced between arms. At the primary analysis (median follow-up ~15 mos), consistent PFS benefit was seen with IRd regardless of prior PI or thal/R exposure (Table). CR+VGPR rates with IRd vs placebo-Rd appeared generally similar in PI-naïve (54% vs 37%), PI-exposed (46% vs 40%), thal/R-naïve (51% vs 44%), thal/R-exposed (45% vs 35%), R-naïve (48% vs 39%), and R-exposed (45% vs 36%) pts, but lower in thal-refractory (30% vs 27%) pts. At a 23-mos analysis, IRd safety profile was consistent regardless of prior PI or thal/R exposure; rates of grade ≥ 3 AEs with IRd vs placebo-Rd were 76% vs 66% in PI-naïve, 73% vs 70% in PI-exposed, 75% vs 71% in thal/R-naïve, and 73% vs 67% in thal/R-exposed pts. Conclusions: The benefit of IRd vs placebo-Rd appeared consistent across subgroups defined by prior PI and thal/R exposure, with a consistent safety profile with IRd. Clinical trial information: NCT01564537.Median PFS, mos. Subgroup IRd, N = 360 Placebo-Rd, N = 362 HR PI naïve (n = 110 vs 109) NE 15.7 0.75 Bortezomib (Btz) naïve (n = 112 vs 112) NE 15.9 0.75 PI exposed (n = 250 vs 253) 18.4 13.6 0.74 Btz exposed (n = 248 vs 250) 18.5 13.6 0.75 Thal/R naïve (n = 167 vs 158) 20.6 13.6 0.70 R (n = 316 vs 318) / Thal naïve (n = 203 vs 192) 20.6/20.6 13.6/13.6 0.77/0.69 Thal/R exposed (n = 193 vs 204) NE 17.5 0.74 R exposed (n = 44 vs 44) NE 17.5 0.58 Thal exposed (n = 157 vs 170) / refractory (n = 40 vs 49) NE/16.6 15.7/13.0 0.75/0.73

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.441
Teacher spread0.355 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207